| Howard Louie - Chairman & Chief Executive Officer Howard Louie, a co-founder of the company, has served as a founder, director and/or officer in leading the management team of several public companies over the past 20 years. At the executive management level, he has been involved in the process of restructuring and advising both private and public companies regarding mergers and acquisitions, capital and investment financing, and international business development, as well as joint-venture and market-penetration strategies. During his distinguished career, Mr. Louie has successfully implemented business strategies on international market penetration for various business initiatives. This has included identifying, negotiating and completing cross-border transactions resulting in joint ventures and or licensing agreements with market-dominating multinationals, and bringing together international investment capital. His past non-business directorships include acting as a member of the board for the Sunnyhill Children's Hospital and Overseas Council Canada - a privately funded organization that provides scholarships and facility development for third-world educational development. Mr. Louie continues to be active in the non-profit sector, including long-standing volunteer work with international aid groups, with a particular focus on needy children. For business and leisure, Mr. Louie enjoys long-time memberships with the Royal Vancouver Yacht Club and the Vancouver Club. | |
| Garth Greenham - President Garth Greenham's experience includes 15 years in management with Johnson & Johnson (McNeil Pharmaceutical), where he directed many key global product markets in the human health care area. After Johnson & Johnson, Mr. Greenham became director of sales, marketing and operations for Aqua Health Ltd. where, over a nine-year period, he helped the company grow into the world leader in the field of animal vaccines, primarily aquaculture. Aqua Health was a subsidiary of Cobequid Life Sciences, a TSE-listed company purchased in 2000 by Novartis Inc. He subsequently served as president and director of the post-acquisition company. Mr. Greenham is a co-founder of Phycobiologics Inc. (recently acquired by Functional Technologies) and currently also serves on the board of the Prince Edward Island BioAlliance. | |
| Kito Tosetti - Chief Operating Officer Mr. Tosetti possesses more than 28 years of experience in the design and execution of major industrial systems and projects in the beverage and food industries, as well as in the development and executive management of medical and health care technology assets in the life science industries. Mr. Tosetti has held senior executive roles in the life science Industry, including as Chief Executive Officer of iCell Therapeutics Corp. and MIV Therapeutics Inc. More recently, Mr. Tosetti has been involved in advising and securing licensing and/or funding opportunities for various organizations including Axela Inc., Brazil's Ministry of Health/CERTI Foundation, as well as portfolio companies of various venture capital firms. Mr. Tosetti's vast experience in the beverage and food industry include his role as President and founder of MVM Engineering Ltd., an engineering design and manufacturing firm involved in the design and installation of equipment and quality control systems in the beverage industry. There, he was instrumental in cultivating and executing comprehensive projects for significant clients including various international franchise plants of Coca-Cola Company and PepsiCo Inc., Cadbury Schweppes Inc., and Kaiser Brewery S.A. | |
| Dr. Michael Horne - Chief Scientific Officer Michael Horne is an internationally regarded scientist who has led numerous scientific teams in the successful development and production of commercial human and animal healthcare products. Dr. Horne has demonstrated expertise in micro-organism product development in the commercial business sector. Most recently, he held the position of Director of Research in the animal health division of Novartis AG. While at Novartis, he played a leading role in the expansion of the company's aquaculture franchise, including the development of the world's first commercialized, fully licensed DNA vaccine. He is the author of more than 100 technical, scientific and general publications, and participates on numerous international scientific committees. As the company's chief scientific officer, Dr. Horne will devote himself full-time to leading and mentoring Functional Technologies' growing research and development team; supporting the commercial development and rollout of the company's proprietary Phyterra-branded yeast and micro algae-derived products; and expanding the company's product pipeline through the development of new and next-generation products and technologies identified as having commercial market applications in the functional foods and health products markets. He will be based in the United Kingdom in order to provide the company with key visibility in the important European market, and to help facilitate Functional Technologies' future expansion into Europe. | |
| Christopher Morris, PhD - Interim Chief Financial Officer Mr. Morris has more than 12 years of experience in the finance industry including senior roles in corporate finance, capital markets, and restructuring initiatives. Mr. Morris is founder and President of R.C. Morris & Company, which provides various financial, advisory and consulting services to companies, investors and executives, and has previously held several senior executive roles in both private and public companies. Mr. Morris holds a PhD from Cambridge University. | |
| Connie Chen, PhD - Vice President, Corporate Development and Communications Dr. Chen joined Functional Technologies Corp. with over five years of experience in small-to-mid cap biotech equity research and capital markets at independent Canadian investment banks. Over the years, she has conducted numerous comprehensive company and industry analyses in the biotech, life sciences and special situations sectors, assisted in financing early and mid-stage companies, and communicated investment ideas and recommendations primarily to institutional clients in North America and Europe. Most recently Dr. Chen was a respected Biotechnology and Health Sciences Analyst at Loewen, Ondaatje and McCutcheon Limited. She also brings over nine years of experience in academic scientific and medical research. Dr. Chen holds a PhD in Pharmaceutical Sciences from the University of Toronto, with a focus in carcinogenesis and reproductive toxicology, and an Honours BSc in Biochemistry from McMaster University. | |
| Geoffrey Lee, MBA - Vice President, Business Development Geoff Lee, co-founder of the company, has served in leading management positions with several private and public companies. His business initiatives have involved concept development, product creation, investment analysis and business development, operations management and implementation, and the internationalization of commercial services and technologies. Geoff has successfully initiated and implemented strategies that have enabled several companies to develop into market leaders in their business sectors. This history includes developing and implementing one of the most progressive restaurant and wine merchandising programs in North America; identifying and securing relationships with market-leading multinational companies to bring businesses, and innovative products and brands, to an international marketplace in the technology sector; internationalizing businesses to enable successful operation in local markets; and raising strategic investment capital. Most recently, Geoff worked with senior management to establish Functional Technologies' wholly owned operating company in Napa Valley, California. |